Published monthly, the International Journal of Dermatology is specifically designed to provide dermatologists around the world with a regular, up-to-date source of information on all aspects of the diagnosis and management of skin diseases. Accepted articles regularly cover clinical trials; education; morphology; pharmacology and therapeutics; case reports, and reviews. Additional features include tropical medical reports, news, correspondence, proceedings and transactions, and education. The International Journal of Dermatology is guided by a distinguished, international editorial board and emphasizes a global approach to continuing medical education for physicians and other providers of health care with a specific interest in problems relating to the skin.
AbstractBackground. The present study reports the incidence of trichocutaneous disorders studied in 500 patients infected with HIV I in a large university‐based setting. Correlation of these findings with immunologic function at the time of diagnosis is presented. Unusual presentations and therapeutic interventions are discussed. Prognosis as related to various trichocutaneous disorders is elaborated.Methods. All patients in this study were hivi positive by Western blot assay. T‐cell subsets were evaluated by monoclonal antibodies against T‐cell surface markers. Hair disorders were analyzed by means of light hair pull test, hair mount, polarizing microscopy, trichogram, scalp biophsy, and cultures for bacteria, fungi, and mycobacteria as indicated. Trichologic manifestations were classified based upon immunologic correlation of absolute level of helper T cells/mm3.Results. The majority of hair disorders in the study population occurred with helper T cell numbers of less than 150/mm3. Papulosquamous problems including seborrheic dermatitis and psoriasis were most commonly noted followed by disorders of cell growth cycle regulation and trichokeratinization, i.e., telogen effluvium and loose anagen syndrome.Conclusions. Multiple trichocutaneous disorders occur in the setting of retroviral infection. Most of these disorders occur in the setting of progressive immunoincompetence. The awareness of the disorders described here will aid the clinician in both the recognition and management of pilar aberrations in the appropriate clinical setting.
Irune Méndez Maestro, Lander Peña Merino, Begoña Udondo González del Tánago, Aida Aramburu González, Ana Orbea Sopeña, J. Vicente, Juan Antonio Ratón Nieto, Elvira Acebo Mariñas, Jesús Gardeazábal García
AbstractBackgroundCOVID‐19 cutaneous manifestations have been recently described and classified in five different clinical patterns, including acral erythema‐edema (pseudo‐chilblain), maculopapular exanthemas, vesicular eruptions, urticarial lesions, and livedo or necrosis.ObjectivesThe objective of this study was to examine the skin of hospitalized patients with a confirmed diagnosis of COVID‐19 disease and describe the real prevalence of skin manifestations.MethodsA cross‐sectional study, which included hospitalized patients in Cruces University Hospital from April 14–30, 2020, with a laboratory‐confirmed diagnosis of COVID‐19 (with polymerase chain reaction and/or serology tests), was conducted. Entire body surface examination was performed by experienced dermatologists to search for cutaneous manifestations related to COVID‐19 disease.ResultsFrom a sample of 75 patients, 14 (18.7%) developed cutaneous manifestations possibly related to COVID‐19. We found six patients with acral erythema‐edema (pseudo‐chilblain) (42.8%), four patients with maculopapular exanthemas (28.6%), two patients with urticarial lesions (14.3%), one patient with livedo reticularis‐like lesions (7.15%), and one patient with vesicular eruption (7.15%).ConclusionsOur study provides a more plausible relationship between the main cutaneous patterns and COVID‐19 in hospitalized patients as all of them had a confirmatory laboratory test. Skin manifestations are frequent but mild with spontaneous resolution. These findings are nonspecific and can be similar to other viral infections and adverse drug reactions in hospitalized patients.